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Background: With the introduction of artemisinin-based combination therapy (ACT) in 2005, monitoring of anti-malarial
drug efficacy, which includes the use of molecular tools to detect known genetic markers of parasite resistance, is
important for first-hand information on the changes in parasite susceptibility to drugs in Ghana. This study investigated
the Plasmodium falciparum multidrug resistance gene (pfmdr1) copy number, mutations and the chloroquine resistance
transporter gene (pfcrt) mutations in Ghanaian isolates collected in seven years to detect the trends in prevalence
of mutations.
Methods: Archived filter paper blood blots collected from children aged below five years with uncomplicated
malaria in 2003–2010 at sentinel sites were used. Using quantitative real-time polymerase chain reaction (qRT-PCR),
756 samples were assessed for pfmdr1 gene copy number. PCR and restriction fragment length polymorphism (RFLP)
were used to detect alleles of pfmdr1 86 in 1,102 samples, pfmdr1 184, 1034, 1042 and 1246 in 832 samples and pfcrt
76 in 1,063 samples. Merozoite surface protein 2 (msp2) genotyping was done to select monoclonal infections for
copy number analysis.
Results: The percentage of isolates with increased pfmdr1 copy number were 4, 27, 9, and 18% for 2003–04, 2005–06,
2007–08 and 2010, respectively. Significant increasing trends for prevalence of pfmdr1 N86 (×2 = 96.31, p <0.001)
and pfcrt K76 (×2 = 64.50, p <0.001) and decreasing trends in pfmdr1 Y86 (×2 = 38.52, p <0.001) and pfcrt T76
(×2 = 43.49, p <0.001) were observed from 2003–2010. The pfmdr1 F184 and Y184 prevalence showed an increasing and
decreasing trends respectively but were not significant (×2 = 7.39,p=0.060; ×2 = 7.49, p = 0.057 respectively). The pfmdr1
N86-F184-D1246 haplotype, which is alleged to be selected by artemether-lumefantrine showed a significant increasing
trend (×2 = 20.75, p < 0.001).
Conclusion: Increased pfmdr1 gene copy number was observed in the isolates analysed and this finding has
implications for the use of ACT in the country although no resistance has been reported. The decreasing trend in the
prevalence of chloroquine resistance markers after change of treatment policy presents the possibility for future
introduction of chloroquine as prophylaxis for malaria risk groups such as children and pregnant women in Ghana.
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Malaria is a childhood killer disease in sub-Saharan Africa.
Consequently, the absence of an effective malaria vaccine
and low uptake of currently available preventive tools
makes chemotherapy a strong pillar of the strategies to
control malaria in disease-endemic areas of the world.
However, the emergence and spread of clones of Plasmo-
dium falciparum which are resistant to most available
anti-malarial drugs makes the control of the disease diffi-
cult to achieve. Since the first report of chloroquine-
resistant P. falciparum in Thailand [1] and the rapid
spread of resistance worldwide, followed by the recom-
mendation by WHO to use artemisinin-based combin-
ation therapy (ACT), many countries in malaria-endemic
areas have been monitoring anti-malarial drug resistance.
Active implementation of malaria surveillance and the
exploitation of molecular as well as phenotypic methods
to characterize parasite drug susceptibility profiles will ex-
pedite the clarification of spatio-temporal drug sensitivity.
This will enable early detection of resistance to the artemi-
sinin derivatives and more efficient use of other available
anti-malarial drugs.
Chloroquine resistance has been linked to single nu-
cleotide polymorphisms (SNPs) in the P. falciparum
transporter gene (pfcrt) on chromosome 7 [2]. The level
of parasite resistance to this drug is under multilocus/
multigenic control [3]. Sets of SNPs in pfcrt codons 72,
74, 75, 76, 97, 152, 163, 220, 271, 326, 356 and 371 were
associated with chloroquine resistance in P. falciparum
from Southeast Asia, Africa and South America [4-6].
The mutation on codon 76, that results from the substi-
tution of threonine for lysine in the gene sequence is the
seminal SNP for producing the resistance phenotype and
the most reliable molecular marker of chloroquine re-
sistance among the various mutations identified [5,6].
In addition there is reported link between T76 and AQ
resistance, however the association is comparatively
weaker to that of the other aminoquinoline chloroquine
[7-11]. Another genetic mechanism of chloroquine resist-
ance is the SNPs in the P. falciparum multidrug-
resistance gene (pfmdr1) on chromosome 5 which en-
codes a P-glycoprotein homologue-1 multi-drug resistant
transporter located in the parasite food vacuole, and is
associated with enhanced efflux of the drug from resist-
ant parasites [12]. The pfmdr1 mutations linked to anti-
malarial drug resistance occur at codons 86, 184, 1034,
1042 and 1246 [12-15]. However, the mutation that
occurs as a result of the substitution of asparagine
for tyrosine at position 86 is linked with chloroquine re-
sistance [12,14,16-19]. Additionally, multiple pfmdr1 SNPs
have been associated with susceptibility profiles of many
anti-malarial drugs. These SNPs, as well as the gene amp-
lification, may alter substrate specificity for aminoquino-
lines and arylaminoalcohols [20] promoting P. falciparumresistance to diverse anti-malarials, including chloro-
quine, mefloquine, quinine and artemisinin derivatives.
The Y184F, N1042D and D1246Y mutations are associ-
ated with the chloroquine resistance phenotype from
samples in Africa, Asia and South America [3,21,22]. The
pfmdr1 haplotype of N86, F184 and D1246 (NFD) were
selected in recrudescence samples after artemether-
lumefantrine (AL) treatment suggesting that this haplo-
type conferred a fitness advantage upon AL pressure
[23]. With the introduction of AL use in Tanzania and
Mozambique, the trends in NFD prevalence have been
shown to be increasing [24-26] which is supports the fact
of AL pressure. In addition, the pfmdr1 N86 and pfcrt
K76 wild-type alleles are also selected by AL treatment but
this observation was not made in the use of artesunate-
amodiaquine (AS-AQ) and amodiaquine-sulphadoxine-
pyrimethamine (AQ-SP) [27]. The pfmdr1 D1246Y and
N86Y mutations predict resistance and recrudescence to
AQ and quinine in Uganda [28]. The N86Y mutation in-
creases sensitivity to artemisinin and dihydroartemisinin-
piperaquine (DHAP) [20]. The N86Y, Y184F and N1042D
mutations increased susceptibility to aryl-amino-alcohol
drugs, including mefloquine, halofantrine, lumefantrine,
and artemisinin derivatives [28-32]. In South America, the
S1034C, N1042D and D1246Y mutations are associated
with quinine resistance [33] and are also implicated in in-
creased sensitivity to artemisinin [34,35]. The S1034C and
N1042D mutations were reported to reduce or abolish re-
sistance to mefloquine [30].
The pfmdr1 gene expression levels have been consid-
ered in the etiology of the parasite resistance to some
anti-malarial drugs and it is being explored in epidemio-
logical studies. Increase in pfmdr1 gene copy number
has been linked to P. falciparum diminished susceptibil-
ity to anti-malarial drugs, such as mefloquine, AS-MQ
and AL combinations [36-38]. Although there is no re-
ported correlation of pfmdr1 gene copy number and treat-
ment failure, this marker is important for the prediction of
recrudescence with the use of the anti-malarials men-
tioned above [39]. There is an assertion that pfmdr1 gene
copy number rather than the SNPs exercises greater influ-
ence in mediating anti-malarial drug resistance to some
compounds [40]. This was reported to be due to the fact
that many transporter proteins mandate concerted com-
plementary attention to copy number variations (CNV) in
mediating anti-malarial activity [40].
Ghana is a malaria-endemic country using ACT (AS-
AQ, AL and DHAP) for the treatment of uncomplicated
malaria since 2005. Information from molecular investiga-
tions, in addition to in vivo and in vitro analysis, is crucial
for early detection and prediction of resistance to the
ACT. Before the change of the drug policy in Ghana, the
prevalence of the pfcrt T76 mutation and the pfmdr1 Y86
mutation associated with chloroquine resistance ranged
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tinel sites [16]. Due to the Malawian and Kenyan experi-
ences where there was significant decrease in the resistant
parasite populations when the drug was withdrawn from
use [41,42], it is expected that a similar phenomenon may
occur in Ghana. Thus the continuous monitoring of the
prevalence of these mutations in parasites in the country
is important. Such information is crucial for consideration
of chloroquine as prophylaxis for malaria risk groups like
children and pregnant women. With the use of ACT in
the country, pfmdr1 copy number determination will help
in the early detection of artemisinin derivatives resistance
which has implications for chemoprophylactic drug recom-
mendations for natives and travelers from non-endemic re-
gions. This study investigated the prevalence of mutations
in pfcrt and pfmdr1 genes as well as the gene copy number
of pfmdr1 in clinical isolates collected from nine sentinel




Samples used in this investigation were collected from
2003–2010 from nine sentinel sites in Ghana established
for monitoring anti-malarial drug resistance in the coun-
try. These sites are located in the three ecological zones
of Ghana: Begoro, Bekwai, Hohoe, Sunyani and Tarkwa
are located in the tropical forest ecological zone and ex-
perience perennial malaria transmission. Navrongo, Wa
and Yendi are in the Guinea Savanna ecological zone and
experience seasonal malaria transmission. Cape-Coast is in
the Coastal Savanna ecological zone and experience peren-
nial malaria transmission.
Study samples
Blood samples were collected from children aged six to
59 months presenting with uncomplicated malaria at the
sentinel sites after the parents or guardians of these chil-
dren gave informed consent for the children to partici-
pate in the study [43-45]. Filter-paper blood blots were
made for each child, air-dried and stored in zip-locked
bags with silica gel at room temperature until use.
Determination of pfmdr1 gene copy number
In all, 756 filter paper, blood-blot samples collected from
2003–2010 were used for the pfmdr1 copy number (CN)
determination. The real-time quantitative PCR (qRT-PCR)
method was used following a published protocol [36].
Parasite DNA was extracted using the QIAamp DNA
Blood Mini Kit. The pfmdr1 gene copy number was esti-
mated for all the parasite isolates by the relative ΔΔCt
method [36]. The DNA from P. falciparum cell lines 3D7,
K1, W2mef and DD2 with copy numbers of 1, 1, 2 and
3–4, respectively were used as references. Samples wererun in triplicates for the quantitative PCR and repeated
additional times for samples with estimated CN values
above 1.5. The estimated CN values were rounded to the
nearest integer. For the selection of monoclonal infec-
tions from the entire data, the merozoite surface protein
2 (msp2) genotyping analysis was done on all 756 sam-
ples for FC27 and IC1 genotypes following published
protocols [46,47]. Monoclonal infections were selected
samples with only one msp2 genotype; either FC27 or
IC1with one PCR band seen on the electrophoresis gel,
which were scored by two people.
Detection of pfmdr1 and pfcrt polymorphisms
In all, 1,102 samples were analysed for the pfmdr1 poly-
morphisms at codon 86 (asparagine to tyrosine) and 832
samples for codons 184 (tyrosine to phenylalanine), 1034
(serine to cysteine), 1042 (asparagine to aspartic acid) and
1246 (aspartic acid to tyrosine). For pfcrt polymorphism at
codon 76 (lysine to threonine), 1,063 samples were ana-
lysed. DNA was extracted from the filter-paper blood blots
using the Tris EDTA buffer extraction method [48]. PCR
followed by restriction fragment length polymorphism
(RFLP) was used to detect the mutations using published
protocols for pfmdr1 [13] and pfcrt [5].
Data analysis
The percentage of isolates with increased pfmdr1 gene
copy number was determined for each sentinel site for the
time points; 2003–04, 2005–06, 2007–08, and 2010. The
data were then pooled for the percentage of Ghanaian
isolates with increased copy number and the observed
trend determined. The prevalence of mutations for pfmdr1
gene codons 86, 184, 1034, 1042 and 1246 and pfcrt codon
76 were determined for each site and an overall data
was pooled from the sites for the Ghanaian isolates
analysis. The significance of the observed trends in the
prevalence of the alleles over the years from 2003 to 2010
was determined using the Chi-squared test for trends
(EpiCalc 2000).
Ethics
Ethical approval for this study was received from the
Noguchi Memorial Institute for Medical Research Institu-
tional Review Board (NMIMR IRB) and the United States
Naval Medical Research Unit No 3 (NAMRU-3) IRB.
Results
Increased pfmdr1 gene copy number in Ghanaian isolates
Seven-hundred and fifty-six (756) samples were analysed
for the detection of pfmdr1 gene copy number. Of these,
47 samples (6.3%) were collected in 2003–2004, 171
(22.7%) were collected in 2005–06, 415 (54.9%) collected
in 2007–08, and 121 (16%) collected in 2010. From the
MSP2 genotyping analysis done, 53.2% (25/47) of the
Table 2 Percentage of isolates with increased pfmdr1
gene copy number in monoclonal infections for each site
per year
Sites %CN> 1
2003-04 2005-06 2007-08 2010
Begoro - 42 (8/19) 0 (0/38) 0 (0/9)
Bekwai - 0 (0/5) 10 (2/22) 20 (2/10)
Cape-Coast - 55 (6/11) 3 (1/32) 7 (1/14)
Hohoe 0 (0/12) - 7 (2/29) -
Navrongo 8 (1/13) 20 (3/15) 3 (1/29) 30 (3/10)
Sunyani - 12 (1/8) 10 (3/30) 0 (0/10)
Tarkwa - 0 (0/2) 27 (4/15) 100 (3/3)
Wa - 0 (0/2) 12 (4/33) 33 (3/9)
Yendi - 20 (4/20) 17 (6/35) 18 (2/11)
Total 4 (1/25) 27 (22/82) 9 (23/263) 18 (14/76)
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band seen) or IC1 allele (one PCR band seen) and, there-
fore, were termed as monoclonal infections. For the
2005–06, 2007–08 and 2010, 48% (82/171), 63.4% (263/
415) and 62.8% (76/121), respectively, had monoclonal
infections. The total number of samples with monoclo-
nal infections (as defined with MSP2 genotyping) used
in the data analysis from 2003–2010 was 446 (59%) out
of the 756 samples analysed.
The number of experimental repeats, range and mean ±
standard deviation of the estimated copy number (CN) for
the P. falciparum clones 3D7, K1, W2-mef and Dd2 are
shown in Table 1. The samples with estimated CN values
above 1.5 were repeated for confirmation. The number of
isolates with increased pfmdr1 gene copy number from the
nine sites per year is shown in Table 2. The sentinel sites
with the majority of increased gene copy number per year
were Navrongo (4%, 1/25) for 2003–04, Begoro (10%,
8/82) for 2005–06, Yendi (2.3%, 6/263) for 2007–8, and
for 2010, Tarkwa, Navrongo and Wa (each with 4%, 3/76).
Estimated CN of isolates from monoclonal infections for
all the sites per year are shown in Figure 1. The highest es-
timated CN was 2.5 and the lowest was 0.6 for the isolates
with monoclonal infections.
Decline in the prevalence of pfcrt T76 and pfmdr1 Y86
alleles after change in drug policy
In all, 1,063 samples were analysed for the detection of
the pfcrt codon 76 alleles (K or T) using PCR followed
by RFLP. Of this number of isolates, 324 (30.5%) were
collected in 2003–04, 232 (21.8%) collected in 2005–06,
402 (37.8%) collected in 2007–08, and 105 (9.9%) were
collected in 2010 from the sentinel sites. The prevalence
of the T76 (chloroquine resistance allele) as observed
from the sentinel sites ranged from 50-98% in 2003–04,
73-95% in 2005–06, 50-95% in 2007–08 and 45-80% in
2010. Whilst for K76 (sensitive allele), the ranges of the
prevalence from the sites were 4-52% in 2003–04, 5-30%
in 2005–06, 6-62% in 2007, and 25-76% in 2010. With
regard to the isolates with both alleles of pfcrt codon 76
(K76T), the observed prevalence when the data were
pooled for Ghana are 2, 10% 12, and 20% from 2003–04,
2005–06, 2007–07 and 2010, respectively. The observedTable 1 Estimated pfmdr1 gene copy number of laboratory









3D7 1 30 0.76 - 1.40 1.11 ± 0.15
K1 1 30 0.79 - 1.41 1.16 ± 0.16
W2mef 2 4 1.86 - 2.34 2.11 ± 0.22
DD2 3-4 4 3.43 - 4.06 3.77 ± 0.34trend of the prevalence of the alleles over the years before
and after the change in drug policy is shown in Figure 2A.
The prevalence of the pfcrt 76 alleles for all the sites is
shown in Additional file 1. A significant decreasing trend
in T76 (×2 = 43.49, p < 0.001) and an increasing trend in
K76 (×2 = 64.50, p < 0.001) were observed from 2003 to
2010 (Figure 2A).
The pfmdr1 codon 86 alleles (N or Y) were detected in
1,102 samples. Of this, 324 (29.4%) samples were col-
lected in 2003–04, 272 (24.6%) were collected in 2005–
06, 397 (36%) collected in 2007–08, and 109 (9.9%) in
2010 from the sentinel sites. The prevalence of the re-
sistant allele Y86 for all the individual sites ranged from
48-96% in 2003–04, 31-67% in 2005–06, 36-67% in 2007–
08, and 10- 50% in 2010. For the chloroquine-sensitive al-
lele N86, the prevalence ranged from 34-71% in 2003–04,
65-89% in 2005–06, 71-100% in 2007–08, and 80-100%
in 2010. A general trend of increase in the prevalence
was observed for N86 (×2 = 96.31, p < 0.001) and a de-
crease in Y86 (×2 = 38.52, p < 0.001) alleles from 2003 to
2010 (Figure 2B).
Prevalence of isolates with pfmdr1 codons 184, 1034,
1042 and 1246 alleles
Pfmdr1 codons 184 (Y and F), 1034 (S and C), 1042 (D and
N) and 1246 (D and Y) alleles were detected in 832 sam-
ples. Out of this total number, 54 (6.5%) samples were col-
lected in 2003–04, 272 (32.7%) were collected in 2005–06,
397 (47.7%) were collected in 2007–08, and 109 (13.1%)
collected in 2010. The ranges of prevalence of the pfmdr1
Y184 for all the sites per year are 22-74% for 2003–04, 18-
65% for 2005–06, 30-53% for 2007–08, and 20-60% for
2010. For the pfmdr1 F184 mutant allele, the ranges were
26-78%, 35-82%, 48-70%, and 40-80% for 2003–04, 2005–

































Figure 1 Estimated copy number values for parasite isolates from Ghana per time points. Each dot represents the estimated copy number




Figure 2 Trends in the prevalence of pfcrt codon 76 and pfmdr1 codons 86, 184, 1034, 1042 and 1246 alleles prior to and after the
change in treatment policy. The arrow indicates the period of anti-malarial drug policy change. (A) pfcrt 76, (B) pfmdr1 86, (C) pfmdr1 184,
(D) pfmdr1 1034, (E) pfmdr1 1042 and (F) pfmdr1 1246.
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Figure 3 Trends in the prevalence of pfmdr1 N86-F184-D1246
haplotype prior to and after the change in treatment policy.
The arrow indicates the period of anti-malarial drug policy change.
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Additional file 1. The observed increasing trend of F184
and the decreasing trend in the prevalence of Y184 alleles
did not reach statistical significance (×2 = 7.39, p = 0.060;
×2 = 7.49, p = 0.057, respectively) (Figure 2C).
The wild type allele of pfmdr1 1034 (S1034) was pre-
dominant in the isolates from all the time points. The
prevalence of the isolates with the allele was 100% for
2003–04, ranged from 92-100%, 98-100%, and 95-100%
for 2005–06, 2007–08 and 2010, respectively. The high-
est prevalence of the mutant C1034 was 35% and was
seen in isolates from Wa (2010). The prevalence of the
pfmdr1 codon 1034 alleles for all the sites per year is
shown in Additional file 1. The prevalence of the alleles
was stable through the time points (Figure 2D).
The pfmdr1 N1042 allele, which is the wild type allele,
was present in majority of the isolates such that all the
samples from 2003–04 had the allele (100%). The preva-
lence of the allele for 2005–06, 2007–08 and 2010 ranged
from 97-100%, 98-100% and 65-100%, respectively. For
the mutant allele, D1042, the highest prevalence of 73%
was observed in isolates from Begoro (2010). The preva-
lence of the pfmdr1 codon 1042 alleles for all the sites per
year is shown in Additional file 1. There was stability in
the prevalence of the pfmdr1 codon 1042 alleles over the
years (Figure 2E).
The codon 1246 wild type allele was present as the
majority allele in the isolates for all the time points. The
prevalence ranged for 2003–04, 2005–06, 2007–08 and
2010 from 96-100%, 80-100%, 94-100%, and 75-100%,
respectively. For the mutant allele, Y1246, the highest
prevalence was 35%, which was observed in the isolates
from Cape-Coast (2010). The prevalence of the pfmdr1
codon 1246 alleles for all the sites per year is shown in
Additional file 1. The prevalence of the alleles was stable
over the years (Figure 2F).
The prevalence of isolates with the pfmdr1 N86-F184-
D1246 (NFD) haplotype showed a significant increasing
trend (×2 = 20.75, p <0.001) (Figure 3). For the Y86-F184-
D1246 haplotype, the prevalence observed for 2003–04,
2005–06, 2007–08, and 2010 was 31.5, 25.0, 31.0 and
18.3%, respectively. Whilst for the Y86-Y184-Y1246 haplo-
type, the prevalence was 4.0, 6.0, 5.0, and 5.0% for 2003–
04, 2005–06, 2007–08, and 2010, respectively. The pfmdr1
wild type N86-Y184-S1034-N1042-D1246 haplotype was
present in 35.2, 33.5, 32.5, and 26.6% of the isolates,
respectively for 2003–04, 2005–06, 2007–08, and 2010.
Discussion
In the absence of any reported parasite resistance to
ACT in Ghana, the increased pfmdr1 gene copy number
observed in this study indicates the possibility of nascent
clones of P. falciparum with reduced susceptibility to the
artemisinin derivatives in the country. The high frequencyof malaria in Ghana, coupled with a solitary reliance on
ACT treatment, poses a situation where selection and
propagation of drug-resistant lineages is highly possible.
The malaria treatment policy was changed in 2005 from
the use of chloroquine as first-line drug to the use of AS-
AQ, and in 2008, AL and DHAP were added as the first-
line drugs for the treatment of uncomplicated malaria in
Ghana. The data showed that before the change, 2003–04,
only one parasite out of the 25 isolates tested had increased
copy number of 2. This outcome, which is expected, re-
flects the absence of the artemisinin derivatives and meflo-
quine drug pressure as these drugs were in limited use at
that time. However, it is interesting to note that soon after
the implementation of the new malaria drug policy in
2005–06, 27% of the isolates showed an increased pfmdr1
gene copy number, which was the highest of the four time
points. This observation can be attributed to the drug pres-
sure induced by the increased use of the artesunate, a com-
ponent in the ACT.
Although there is no evidence data on the use of arte-
sunate in the country before 2005, due to the low sensi-
tivity of parasites to chloroquine then, there was limited
use of the drug as monotherapy for the treatment of
uncomplicated malaria (Neils B. Quashie, pers comm).
After 2005–06 there was a decline from 27% in 2005–6
to 9% in 2007–08 with the introduction of the other two
ACT, AL and DHAP. There was an increase from 9% to
18% of isolates with copy number increase in 2010. The
observed trend of the parasites with increased copy num-
ber at the designated time points in the surveillance is sug-
gestive that there is circulation of parasites with reduced
sensitivity to artemisinin derivatives and mefloquine in
Ghana. Of the three ecological zones in Ghana, isolates
from the three savanna zone areas had the majority with
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Yendi for 2007–08, Wa and Navrongo for 2010. It is,
therefore, not surprising that Abuaku and others reported
a delayed clearance of parasites with the use of AL, espe-
cially with parasites from the savannah zone [43]. This
finding adds credence to the assertion that gene copy
number variation (CNV) may be the suitable indicator for
incipient delays in parasite clearance with the use of ACT.
CNV in this case involves the duplication of multi-drug
resistance genes which help the parasite to survive under
unfavourable drug conditions and as such the pfmdr1
increased copy number is alleged to confer resistance to
some ACT and a decrease in the gene copy numbers may
confer sensitivity to some anti-malarials [49-51].
The increased pfmdr1 gene copy number being re-
corded in sub-Saharan Africa can be worrying although
it is not a good indicator of ACT sensitivity in SE Asia it
is important to monitor the prevalence of this marker in
the circulating parasite population. With ACT use and
vector control, the expectation of reduction in mortality
and morbidity in African children will be dwindled with
the emergence and spread of resistant parasites to the
newly introduced ACT. Since the first report of ACT re-
sistance in Southeast Asia and the associated pfmdr1 gene
copy number, the gradual movement of these parasites
into Africa is being seen. Increased pfmdr1 gene copy has
been reported in West African countries such as Côte
d’Ivoire, Burkina Faso, Togo [52], Senegal [30], but not in
Nigeria [23], the Gambia (David J Conway, pers comm),
Liberia and Guinea Bissau [53]. Other African countries
with reported increased pfmdr1 copy number in isolates
includes Kenya [9], Gabon [31] and Sudan [54] but not in
Cameroon [27] and Mozambique [55].
Chloroquine was the first-line drug for the treatment
of uncomplicated malaria in Ghana before the change to
the use of ACT. In 2007 Koram's group reported the as-
sociation between the molecular markers of chloroquine
resistance, pfcrt T76 and pfmdr1 Y86 with drug treat-
ment failure in a clinical study [16]. This report [16]
together with that from in vivo [45] and in vitro [56]
studies ran in parallel, which was made available to the
National Malaria Control Programme (NMCP), became
one of the basis for treatment policy change in the coun-
try. Since then, there has been continuous monitoring of
anti-malarial drug resistance in the country using the
three aspects of investigation named above. An increas-
ing trend in the prevalence of the pfcrt K76 wild type al-
lele from 19 to 59% from 2005 to 2010 and a decreasing
trend for pfcrt T76 from 88 to 56% for the same period
were observed. The general observation depicts a decline
of pfcrt T76 with and a gradual takeover by K76 after
chloroquine was removed in 2005 as the first choice of
anti-malarial treatment. This observed trend in Ghana is
consistent with observations of decreasing trend of themutants in Malawi, where the decrease was from 85 to
13% for 1993 to 2000 [41], Kenya, a decrease from 95 to
60% for 1993 to 2006 [42], Senegal, a decrease from 92
to 37% for 2000 to 2010 [30] and Mozambique, from 96
to 32% for 2006 to 2010 [55]. The significant decrease in
the prevalence of pfcrt T76 in Ghana is indicative of the
fitness, which is low for the resistant allele after the
selective drug pressure has been withdrawn. This same
scenario was observed for pfmdr1 N86Y, where there
was a decline in the prevalence of the mutant from 46 to
28% for 2005 to 2010 and an increase in the prevalence
of the wild type strains N86 from 77 to 86%. Similar ob-
servations have been made in other studies conducted in
Africa where K76T and N86Y were investigated concur-
rently [30,41,55]. In this study, there was no significant
difference between the prevalence of N86 for 2007–08
and 2010, which were 89 and 86%, respectively. This is
indicative of a gradual gaining of stability of these geno-
types in the population similar to what was observed by
Nzila’s group in Kenya [42].
Despite the comparatively faster decline of T76 in the
population, the Y86 seems to reduce slowly in this inves-
tigation. A study conducted in Gabon with isolates col-
lected from 2004 and 2009, showed stability in T76 with
94% in 2004 and 96% in 2009 whilst the Y86 increased
from 16 to 31% for 2004 and 2009 [57]. The apparent
disappearance of the chloroquine-resistant parasites with
pfcrt T76 and pfmdr1 Y86 from most of the sub-Saharan
Africa malarious areas will help in the re-introduction of
the cheapest anti-malarial in combination with an arte-
misinin derivative. The presence of the mutant parasites
with pfcrt T76 and pfmdr1 Y86 is a threat to some of
the ACT in use. It is important to note that the preva-
lence of T76 in 2003–04 was 70% and in the year of im-
plementation of AS-AQ in 2005, the prevalence went up
to 88%, which is suggestive that another aminoquinoline,
in this case, AQ selected the pfcrt codon 76 mutants.
This is similar to observations made in studies con-
ducted in Uganda and Burkina Faso [11,28,32]. A report
from an in vitro study conducted in Nigeria showed an
association between the T76 mutation and decreased
susceptibility to artemether [58]. The increasing trend in
the prevalence of N86 observed in this study must be
closely monitored since this allele is reportedly linked to
decreased sensitivity of parasites to lumefantrine and
mefloquine and it is also a marker for lumefantrine tol-
erance [57]. In addition an increasing trend for K76 will
create a future problem for ACT use because it has been
seen in recrudescent samples after AL use [59].
The prevalence of the other SNPs of the pfmdr1 gene
was also investigated, which included the alleles of co-
dons 184, 1034, 1042 and 1246. The mutant allele of
codon 184 is known to be selected after AL use in recru-
descent samples [54,60]. From the results, in 2003–04,
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2005 and then increased to 62% in 2010. Although the
increasing trend of the prevalence of F184 from 2003 to
2010 was not significant, there is an indication of selec-
tion of this suggested AL resistance allele. Results from a
2010 study conducted in seven communities in southern
Ghana revealed the prevalence of F184 to be about 72%
[61]. In the West African region, a report from a study
conducted in Senegal also showed the prevalence of 68%
in samples collected in 2009–2010 [30]. The wild type
allele, Y184 was observed to be decreasing in prevalence
whilst the other alleles, such as the S1034 wild type
allele, were stable over the time points. An increase in
the prevalence of the mutant (C1034) was observed for
2010. For the codon 1042 alleles, the wild type N1042
was also stable until a decrease in prevalence (from 100
to 92%) was observed in 2010. The mutant D1042 was
also about 19% in 2010 with low to non-existent levels
in the previous years. For the codon 1246 alleles, D1246
dropped from 98% in 2003–04 to 90% in 2010 whilst the
Y1246 was observed to be gradually increasing 7% in
2003–04 to 14% in 2010. The Y1246 mutant has been
linked to quinine failure [57], as such the use of quinine
as second-line drug in Ghana for the treatment of un-
complicated malaria may delay the selection of these
mutant parasites. There is more stability in the three
pfmdr1 codons 1034, 1042 and 1246 compared to the
86 and 184. The haplotype mutant of pfmdr1 C1034-
D1042-Y1246 has been linked to increased sensitivity to
artemisinin [34,35] whilst C1034-D1042 is linked to sensi-
tivity to mefloquine [30]. Furthermore, the Y86-F184-
D1042 mutations have been shown to increase the
susceptibility of parasites to aryl-amino-alcohol drugs,
artemisinin derivatives, mefloquine, halofantrine and
lumefantrine [28-32]. As such the stability of these mu-
tants as observed in this study will help maintain the use
of ACT in the country. The N86-F184-D1246 haplotype,
which was detected in 35% of the isolates in 2003–04,
increased significantly to 53% in 2010. Similar trends in
prevalence for the NFD haplotype have been reported in
Tanzania and Mozambique after the introduction of AL
use [24-26]. In addition, this haplotype as well as pfcrt
K76 were seen in recrudescent samples after AL use
[54,59]. The NFD haplotype therefore needs to be moni-
tored effectively especially in malarious countries using
AL for chemotherapy.
Conclusions
Generally, the observations made in this study with the
prevalence of the molecular markers are in line with
what is expected before and after the change of the mal-
aria treatment policy. The increase in pfmdr1 gene copy
number (although not a good indicator) in some of the
isolates, which is linked to susceptibility of artemisininderivatives, mefloquine, halofantrine and lumefantrine,
has implications for ACT use in Ghana. As the chloro-
quine resistant genotypes decrease in frequency, and sub-
sequently in-vitro data confirms increased susceptibility to
the drug, it can be introduced as prophylaxis for malaria
risk groups, such as children and pregnant women. The
findings draw attention to the need to continually monitor
molecular markers of all the anti-malarial drugs currently
in use in Ghana to allow for early detection of reduced or
increased parasite susceptibility to the drugs. It must be
stressed that findings from this study have given some
insight into the genetic background of the parasites in cir-
culation in Ghana. This will enable genuine conjuncture
into the future of malaria in the country in the context of
the SNPs of anti-malarial drug resistance and the potential
effect of the increasing trends of the drug-resistant para-
site populations. Further monitoring of these markers are
ongoing in Ghana for ACT efficacy, including both in vivo
and in vitro studies.Additional file
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